# Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis

> **NCT06101823** · PHASE2 · UNKNOWN · sponsor: **Opsidio, LLC** · enrollment: 48 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **BIOLOGICAL:** OpSCF
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** OpSCF (Open Label Extension)

## Key facts

- **NCT ID:** NCT06101823
- **Lead sponsor:** Opsidio, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-25
- **Primary completion:** 2024-10
- **Final completion:** 2025-06
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2024-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06101823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06101823, "Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06101823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*